Geneva Advisors LLC increased its stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 13.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 38,538 shares of the medical equipment provider’s stock after buying an additional 4,511 shares during the period. Geneva Advisors LLC’s holdings in Smith & Nephew SNATS were worth $1,343,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in SNN. Bank of Montreal Can increased its stake in shares of Smith & Nephew SNATS by 1.3% in the first quarter. Bank of Montreal Can now owns 23,315 shares of the medical equipment provider’s stock valued at $721,000 after buying an additional 289 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Smith & Nephew SNATS during the first quarter valued at approximately $2,884,000. BB&T Corp increased its stake in shares of Smith & Nephew SNATS by 4.3% in the first quarter. BB&T Corp now owns 79,804 shares of the medical equipment provider’s stock valued at $2,468,000 after buying an additional 3,299 shares during the period. Wells Fargo & Company MN increased its stake in shares of Smith & Nephew SNATS by 21.4% in the first quarter. Wells Fargo & Company MN now owns 429,522 shares of the medical equipment provider’s stock valued at $13,285,000 after buying an additional 75,572 shares during the period. Finally, Eqis Capital Management Inc. increased its stake in shares of Smith & Nephew SNATS by 35.6% in the first quarter. Eqis Capital Management Inc. now owns 39,587 shares of the medical equipment provider’s stock valued at $1,224,000 after buying an additional 10,394 shares during the period. 6.36% of the stock is owned by institutional investors.

Smith & Nephew SNATS, Inc. (NYSE:SNN) opened at 35.95 on Monday. Smith & Nephew SNATS, Inc. has a 12-month low of $26.97 and a 12-month high of $36.22. The stock has a market capitalization of $15.74 billion, a P/E ratio of 18.30 and a beta of 0.76. The firm’s 50-day moving average is $35.14 and its 200-day moving average is $33.36.

ILLEGAL ACTIVITY NOTICE: “Smith & Nephew SNATS, Inc. (SNN) Stake Raised by Geneva Advisors LLC” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/28/smith-nephew-snats-inc-snn-stake-raised-by-geneva-advisors-llc.html.

Several analysts have recently commented on SNN shares. Zacks Investment Research raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Wednesday, June 7th. BidaskClub downgraded shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Smith & Nephew SNATS currently has an average rating of “Buy” and an average target price of $38.00.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Institutional Ownership by Quarter for Smith & Nephew SNATS (NYSE:SNN)

Receive News & Stock Ratings for Smith & Nephew SNATS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS Inc. and related stocks with our FREE daily email newsletter.